:----: :COMPONENT: TILE HERO BLOCK :Eyebrow: 화학 합성 :헤더: 당사의 혁신적 사고와 첨단 화학 공정은 지속 가능성을 향상시키고, 삶의 질을 개선하고, 더 회복력 강한 세상을 만들어 나갑니다. :이미지-BG: 옅은 파란색 배경에 막대로 연결된 투명한 구체로 이루어진 분자 구조를 3D 일러스트레이션으로 표현한 이미지입니다. 이 구조는 원자들이 결합으로 연결된 것처럼 보입니다. :----: :COMPONENT: TEXT BLOCK :헤더: 수십 년 동안 다양한 산업에 걸쳐 쌓아온 경험을 바탕으로 당사는 고객, 시장 및 업계의 요구를 지속적으로 충족하기 위해 필요한 인력과 인프라, 프로세스를 개발해 왔으며, Albemarle만의 고유한 협업 문화를 구축했습니다. :본문:…, -35%, :설명: 2030년까지 당사 특수 화학 사업의 탄소 집약도 감소 :통계-카드: :통계:, +30%, :설명: 화학 용액을 통해 이용 가능한 배터리의 에너지 밀도 향상 효과(추정) :통계-카드: :Stat:, 매우 낮음, :설명: ABZOL® 용매의 오존층 파괴 지수(ODP) 및 지구 온난화 지수(GWP) :BG: 아쿠아 :----: :COMPONENT: SPACER-SMALL-WHITE :----: :COMPONENT: RELATED LINKS BLOCK :헤더:, 용제, 탭: :본문: Albemarle은 증기 탈지, 냉간 세척, 초음파 세척을 위한 고성능 정밀 세척 용제를 포함하여 다양한 환경에서 사용할 수 있도록 엄선하여 제작된 브롬화 특수 용제를 생산합니다. 당사 제품은 오존층 파괴 지수(ODP)가 낮고 지구 온난화 지수(GWP)가 매우 낮습니다. 또한 인화점이 없고, 재활용이 용이하고, 금속과 호환되고, 다른 용매보다 부식을 일으킬 가능성이 적습니다. :Col3-라벨: 관련 :링크-기본: 전기 및 전자제품 :링크-기본: 자동차 :링크-기본: 항공 및 우주 :링크-기본: 의료 기기 및 장비 :링크-기본: 산업 공정 :링크-기본: 제약 및 영양 :링크-기본: ABZOL® :----: :COMPONENT: RELATED LINKS BLOCK :헤더:, 화학 합성을 위한 특수 시약, 탭: :본문: Albemarle은 유기금속 분야에서 뛰어난 반응성과 화학적 변형에 대한 높은 선택성을 모두 보여주는 다양한 시약을 제공합니다. 당사는 다음을 비롯한 주요 화학적 변환에 활용할 수 있는 다양한 리튬, 마그네슘, 아연 및 세슘 기반 시약을 공급합니다. 탈양성자화 할로겐-금속 교환 C-C 결합 반응 절감 :Col3-Label: 관련 :링크-기본: 제약 및 영양 :링크-기본: 농업 및 식품 :----: :COMPONENT: RELATED LINKS BLOCK :헤더:, 첨가제 및 변형제, 탭: :본문: Albemarle의 첨가제와 개질제는 건설, 소비자 전자제품, 가전제품 등 다양한 산업 분야에 걸쳐 사용됩니다. 건설 및 건축 산업에서는 시공 시간을 단축하기 위해 바닥과 벽체에서 빠르게 경화되는 건축 자재의 중요성이 커지고 있습니다. 탄산리튬은 빠른 경화 시멘트와 모르타르의 가속제로 사용되며, 주요 활용 분야로는 자체 수평 조절 바닥 스크리드, 타일용 접착제, 숏크리트 및 방수 슬러리를 들 수 있습니다. 당사는 구체적인 용도에 적합한 수산화리튬, 탄산리튬, 황산리튬을 제공합니다. SAYTEX ® 8010과 같은 브롬계 난연제는 일상적으로 사용하는 제품에 위기 시 생명을 구할 수 있는 특성을 더해주며, 운송 및 디지털화를 위한 신기술을 지원합니다. 일반적인 가정의 경우 평균적으로 20개가…, 촉매 제조용 시약, 탭: :본문: 세슘은 낮은 이온화 전위적 특성으로 이종 공정에서 다양한 금속 산화물 촉매의 성능을 효과적으로 향상시킵니다. 전이 금속의 높은 산화 상태를 안정화시키는 세슘의 특성에 힘입어 이러한 효과가 강화되는 경우가 많습니다. 당사는 독창적인 세슘 처리 기법을 바탕으로 다양한 제품 등급의 수율을 맞춤형으로 구성하여 고객의 다양한 기대에 부응할 수 있으며, 이를 통해 더욱 효과적인 적용이 가능합니다. MgEHOx는 폴리올레핀 촉매 제조에 사용되는 액체 마그네슘 공급원으로서 취급이 매우 용이합니다. 브로민화수소산(HBr)은 AMOCO 공정으로 알려진 파라자일렌의 산화 촉매 공정에서 촉진제로 작용하며, 이는 최종적으로 일상생활에서 흔히 사용되는 합성 섬유인 폴리에틸렌 테레프탈레이트(PET) 제조에 사용됩니다…, , :----: :COMPONENT: SPACER-XSMALL-WHITE :----: :COMPONENT: CTA BLOCK :Header: 문의 :본문: 당사의 화학 합성 솔루션에 대해 문의해 주세요. :기본 버튼: 자세히 알아보기 :BG: 아쿠아
Type: Solution
：----： :COMPONENT: TILE HERO BLOCK :Eyebrow: 化学合成 :Header：我们的创新思维和先进的化学工艺能够提高可持续性、改善生活，并建设一个更具韧性的世界。 :Image-BG: 3d illustration of a molecular structure with transparent spheres connected by rods, resembling atoms linked by bonds, against a soft blue background. ：----： :COMPONENT: TEXT BLOCK :Header: 凭借数十年服务于多种行业的经验，我们已经培养了所需的人才、基础设施、流程和独特的协作文化，以持续满足客户、市场和行业的需求。 :Body: 雅保的开创性高性能化学解决方案为众多行业提供支持，…, -35%, :Description: 2030 年雅保特种化学品业务将实现的碳强度下降目标 ：STAT-CARD： :Stat:, +30%, :Description: 通过化学解决方案可获得的电池能量密度预计提升值 ：STAT-CARD： :Stat:, 极低, :描述：ABZOL® 溶剂的臭氧消耗潜能值 (ODP) 和全球变暖潜能值 (GWP) :BG: Aqua ：----： :COMPONENT: SPACER-SMALL-WHITE ：----： :COMPONENT: RELATED LINKS BLOCK :标题：, 溶剂, :Tab: :Body: 雅保生产的溴化特种精制溶剂可用于各种场景，例如，我们的高性能精密清洁溶剂可用于蒸汽脱脂、低温清洁和超声清洁。 我们的产品具有极低的臭氧消耗潜能值 (ODP) 和全球变暖潜能值 (GWP)，且无闪点、易于回收，并与金属相容，比其他溶剂相比不易造成腐蚀。 :Col3-Label: 相关信息 :Link-Primary: 电气和电子产品 :Link-Primary: 汽车行业 :Link-Primary: 航空航天 :Link-Primary: 医疗器械和设备 :Link-Primary: 工业生产 :Link-Primary: 制药与营养 :Link-Primary: ABZOL® ：----： :COMPONENT: RELATED LINKS BLOCK :Header:, 化学合成用特种试剂, :Tab: :Body：雅保在有机金属领域提供多种试剂，这些试剂在化学转化中表现出卓越的反应性和高选择性。我们供应各种以锂、镁、锌和铯为基础的试剂，用于关键的化学转化，包括： 去质子化 卤素-金属交换 C-C偶联反应 还原反应 :Col3-Label：相关 :Link-Primary: 制药与营养 :Link-Primary: 农业与食品 ：----： :COMPONENT: RELATED LINKS BLOCK :标题：, 添加剂和改性剂, :Tab: :Body: 雅保的添加剂和改性剂被广泛用于建筑、消费电子和家电等多个行业。 在建筑和建造行业中，快速固化的建筑材料在地板和墙壁应用中变得越来越重要，以减少施工时间。碳酸锂用作快凝水泥和砂浆的促进剂，主要应用包括自流平地坪砂浆、瓷砖粘合剂、喷射混凝土和防水浆料。我们提供氢氧化锂、碳酸锂和硫酸锂，用于特定应用。 溴化阻燃剂，例如 SAYTEX ® 8010，为日常产品提供了拯救生命的特性，并支持运输和数字化领域的新兴技术。平均每个家庭拥有超过 20 件电子产品。许多日常用品都是易燃的，可能对人和财产构成风险。SAYTEX® 8010 阻燃剂降低了可燃性，并且在许多情况下，在发生危及生命的火灾时，提供了更多的逃生时间。 诸如双乙二酸硼酸锂 (LiBOB) 等无氟高离解锂盐可为聚合物，尤其是聚氨酯，提供绿色环保的抗静电解决方案。 :Col3-Label：相关信息 :Link-…, 催化剂制备试剂, :Tab: :Body: 铯具有较低的电离势，可有效提升许多金属氧化物催化剂在异相反应过程中的性能，且这一提升效果常常因铯能够稳定过渡金属的高氧化态而得到增强。得益于独特的铯加工工艺，我们能够根据客户的多样化需求量身定制各种等级的产品，并精确控制其产量，使客户能够更高效地应用它们。 MgEHOx 是一种便于操作的液态镁源，用于制备聚烯烃催化剂。 氢溴酸是对二甲苯氧化催化过程（即 AMOCO 工艺）中的促进剂，该工艺的最终目的是生产日常生活中常见的合成纤维——聚对苯二甲酸乙二醇酯 (PET)。由于转化率高，均相催化反应成为商业中最为广泛采用的反应。 雅保的铯化学品已成功应用于以下工业催化过程： 在硫酸生产过程中使用硫酸铯 在氨合成中使用碳酸铯 在多元醇合成过程中使用氢氧化铯 环氧化反应中的氢氧化铯 硝酸铯在 MMA 合成中的应用 用于聚烯烃合成的 MgEHOx 在对苯二甲酸 (PTA)…, , ：----： :COMPONENT: SPACER-XSMALL-WHITE ：----： :COMPONENT: CTA BLOCK :标题: 联系我们 :Body：联系我们，了解我们的化学合成解决方案。 :Button-Primary: 了解更多信息 :BG: Aqua
Type: Solution
CHARLOTTE, N.C. , Nov. 5, 2025 /PRNewswire/ -- Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the third quarter ended September 30, 2025., Third Quarter, , 2025 and Recent Highlights, (Unless otherwise stated, all percentage changes represent year-over-year comparisons), Net sales of $1.3 billion, including volume growth in Energy Storage (+8%) and Ketjen (+8%). Net loss of ($161) million, or ($1.72) per diluted share attributable to common shareholders; Adjusted loss of ($0.19) per diluted share attributable to common shareholders excludes a non-cash goodwill impairment charge associated with Ketjen. Adjusted EBITDA of $226 million; up 7% due to improved fixed…, Third Quarter 2025 Results, In millions, except per share amounts, , Q3 2025, , Q3 2024, , $ Change, , % Change, Net sales $ 1,307.8 $ 1,354.7 $ (46.9) (3.5) % Net loss attributable to Albemarle Corporation $ (160.7) $ (1,069.0) $ 908.3 85.0 % Adjusted EBITDA (b) $ 225.6 $ 211.5 $ 14.1 6.7 % Diluted loss per share attributable to common shareholders $ (1.72) $ (9.45) $ 7.73 81.8 % Non-recurring and other unusual…, Energy Storage Results, In millions, , Q3 2025, , Q3 2024, , $ Change, , % Change, Net Sales $ 708.8 $ 767.3 $ (58.5) (7.6) % Adjusted EBITDA $ 124.1 $ 142.9 $ (18.8) (13.2) % Energy Storage net sales for the third quarter of 2025 were $709 million, a decrease of $59 million, or 8%, due to lower pricing (-16%). Volumes were up 8% due to higher spodumene sales, record production from our integrated…, Specialties Results, In millions, , Q3 2025, , Q3 2024, , $ Change, , % Change, Net Sales $ 345.0 $ 342.4 $ 2.6 0.8 % Adjusted EBITDA $ 75.5 $ 56.3 $ 19.3 34.2 % Specialties net sales for the third quarter of 2025 were $345 million, an increase of $3 million, or 1%, as foreign exchange benefits offset slightly lower volumes (-1%) due to strength in demand for flame retardants in electrical…, Ketjen Results, In millions, , Q3 2025, , Q3 2024, , $ Change, , % Change, Net Sales $ 254.1 $ 245.0 $ 9.1 3.7 % Adjusted EBITDA $ 33.6 $ 35.5 $ (1.9) (5.4) % Ketjen net sales for the third quarter of 2025 were $254 million, up 4% compared to the prior-year quarter as higher volumes (+8%) were partially offset by lower prices (-5%). Adjusted EBITDA of $34 million decreased $2 million…, 2025 Outlook Considerations, Total Corporate Outlook Considerations, Albemarle is enhancing its prior full-year outlook considerations for the enterprise and Energy Storage, which are based on observed lithium market price scenarios. Full-year 2025 results are expected to be towards the higher end of the previously published $9/kg scenario ranges given year-to-date financial performance and lithium market pricing and better-than-expected Energy Storage volumes.…, Total Corporate FY 2025E , Including Energy Storage Scenarios, Observed market price case (a) H1 2025 average H1 2024 range Q4 2023 average Average lithium market price ($/kg LCE) (a) ~$9 $12-15 ~$20 Net sales $4.9 - $5.2 billion $5.3 - $6.1 billion $6.5 - $7.0 billion Adjusted EBITDA (b) $0.8 - $1.0 billion $1.2 - $1.8 billion $2.5 - $2.7 billion (a) Price represents blend of relevant market pricing including spot and regional indices for the periods…, Energy Storage Market Price Scenarios, , Energy Storage FY 2025E , Observed market price case (a) H1 2025 average H1 2024 range Q4 2023 average Average lithium market price ($/kg LCE) (a) ~$9 $12-15 ~$20 Net sales $2.5 - $2.6 billion $2.9 - $3.5 billion $4.2 - $4.5 billion Adjusted EBITDA $0.6 - $0.7 billion $1.0 - $1.5 billion $2.2 - $2.4 billion Equity in net income of unconsolidated investments (net of tax) (b) $0.2 - $0.3 billion $0.3 - $0.5 billion $0.6 - $…, Specialties and Ketjen Outlook Considerations, Specialties outlook reflects volume growth in key end markets led by pharma, automotive and oilfield, partially offset by weakness in building and construction. Ketjen outlook assumes strong fluidized catalytic cracking (FCC) volume offset by lower clean fuel technologies (CFT) volume due to order timing. , Segment FY 2025E, Specialties net sales $1.3 - $1.5 billion Specialties adjusted EBITDA $210 - $280 million Ketjen net sales $1.0 - $1.1 billion Ketjen adjusted EBITDA $120 - $150 million , Other Corporate Outlook Considerations, Albemarle expects its 2025 capital expenditures to be approximately $600 million, down 65% from $1.7 billion in 2024. This level of spending reflects in part a timing impact and a continued prioritization on sustaining existing assets and resources. Reduced corporate costs reflect cost savings and foreign exchange gains to date. , Other Corporate FY 2025E , Capital expenditures ~$600 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $10 - $30 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a) Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b) FY 2025E…, Cash Flow and Capital Deployment, Cash from operations of $894 million in the first nine months of 2025 increased $202 million compared to the prior-year period due to cost and productivity improvements, cash management actions and a customer prepayment received in January. We now expect to achieve positive free cash flow of approximately $300 to $400 million for the full year 2025 given year-to-date financial performance and…, Balance Sheet and Liquidity, As of September 30, 2025, Albemarle had estimated liquidity of approximately $3.5 billion, including $1.9 billion of cash and cash equivalents, $1.5 billion available under our revolver and $107 million available under other credit lines. Total debt was $3.6 billion, representing a net debt to adjusted EBITDA ratio (as defined in our credit agreement) of approximately 2.1 times. In the fourth…, Earnings Call, Date: Thurs., November 6, 2025 Time: 8:00 AM Eastern time Dial-in (U.S.): 1-800-590-8290 Dial-in (International): 1-240-690-8800 Conference ID: ALBQ3 The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com ., About Albemarle, Albemarle Corporation (NYSE: ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity and health. We partner to pioneer new ways to move, power, connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allows us to deliver advanced solutions for our customers. Learn more about…, Forward-Looking Statements, This press release contains statements concerning our expectations, anticipations and beliefs regarding the future, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and…, Three Months Ended, , Nine Months Ended, , September 30,, , September 30,, , 2025, , 2024, , 2025, , 2024, Net sales $ 1,307,829 $ 1,354,692 $ 3,714,702 $ 4,145,813 Cost of goods sold 1,190,219 1,458,726 3,243,917 4,221,487 Gross profit (loss) 117,610 (104,034) 470,785 (75,674) Selling, general and administrative expenses 138,577 154,253 394,536 482,052 Goodwill impairment charges 181,070 — 181,070 — Restructuring charges and asset write-offs 2,275 828,146 5,660 1…, September 30,, , December 31,, , 2025, , 2024, , ASSETS, Current assets: Cash and cash equivalents $ 1,931,758 $ 1,192,230 Trade accounts receivable 733,477 742,201 Other accounts receivable 107,701 238,384 Inventories 1,532,622 1,502,531 Other current assets 249,347 166,916 Total current assets 4,554,905 3,842,262 Property, plant and equipment 12,902,998 12,523,368 Less accumulated depreciation and…, LIABILITIES AND EQUITY, Current liabilities: Accounts payable to third parties $ 780,377 $ 793,455 Accounts payable to related parties 122,794 150,432 Accrued expenses 500,940 467,997 Current portion of long-term debt 445,384 398,023 Dividends payable 61,339 61,282 Income taxes payable 93,120 95,275 Total current liabilities 2,003,954 1,966,464 Long-term debt 3,181,009…, Nine Months Ended, , September 30,, , 2025, , 2024, Cash and cash equivalents at beginning of year $ 1,192,230 $ 889,900 Cash flows from operating activities: Net loss (63,450) (1,220,588) Adjustments to reconcile net loss to cash flows from operating activities: Depreciation and amortization 494,968 425,532 Non-cash goodwill impairment charges 181,070 — Non-cash restructuring and asset write-offs — 1,075,888 Stock-…, Three Months Ended, , Nine Months Ended, , September 30,, , September 30,, , 2025, , 2024, , 2025, , 2024, , Net sales:, Energy Storage $ 708,755 $ 767,291 $ 1,950,976 $ 2,398,299 Specialties 344,960 342,376 1,017,534 993,041 Ketjen 254,114 245,025 746,192 754,473 Total net sales $ 1,307,829 $ 1,354,692 $ 3,714,702 $ 4,145,813 , Adjusted EBITDA:, Energy Storage $ 124,077 $ 142,887 $ 530,157 $ 623,862 Specialties 75,544 56,273 207,187 155,629 Ketjen 33,566 35,473 100,721 95,288 Total segment adjusted EBITDA 233,187 234,633 838,065 874,779 Corporate (7,557) (23,135) (8,816) 14,315 Total adjusted EBITDA $ 225,630 $ 211,498 $ 829,249 $ 889,094 See accompanying non-GAAP…, Additional Information Regarding Non-GAAP Measures, It should be noted that adjusted net income (loss) attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, adjusted diluted loss per share attributable to common shareholders, non-operating pension and other post-employment benefit ("OPEB") items per diluted share, non-recurring and other unusual items per diluted share, adjusted…, ALBEMARLE CORPORATION AND SUBSIDIARIES, Non-GAAP Reconciliations, (Unaudited), See below for a reconciliation of adjusted net income (loss) attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, EBITDA and adjusted EBITDA (on a consolidated basis), which are non-GAAP financial measures, to Net loss attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in…, Three Months Ended, , Nine Months Ended, , September 30,, , September 30,, , 2025, , 2024, , 2025, , 2024, , In thousands, except percentages and per share amounts, , $, , % of net sales, , $, , % of net sales, , $, , % of net sales, , $, , % of net sales, Net loss attributable to Albemarle Corporation ($160,694) $ (1,068,992) ($96,449) $ (1,254,742) Add back: Non-operating pension and OPEB items (net of tax) 189 (344) 483 (1,031) Non-recurring and other unusual items (net of tax) 180,025 928,771 190,533 1,203,313 Adjusted net income (loss)…, EBITDA, 24,183 1.8 % (746,877) (55.1) % 547,945 14.8 % (631,822) (15.2) % Proportionate share of Windfield income tax expense 20,023 1.5 % 99,523 7.3 % 78,499 2.1 % 292,992 7.1 % Non-operating pension and OPEB items 367 — % (331) — % 978 — % (993) — % Non-recurring and other unusual items 181,057 13.8 % 859,183 63.4 % 201,827 5.4 % 1,228,917 29.6 %, Adjusted EBITDA, $225,630 17.3 % $ 211,498 15.6 % $ 829,249 22.3 % $ 889,094 21.4 % Net sales $ 1,307,829 $ 1,354,692 $ 3,714,702 $ 4,145,813 Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to…, Three Months Ended, , Nine Months Ended, , September 30,, , September 30,, , 2025, , 2024, , 2025, , 2024, Interest cost $ 8,976 $ 8,523 $ 26,710 $ 25,529 Expected return on assets (8,609) (8,854) (25,732) (26,522) Total $ 367 $ (331) $ 978 $ (993) In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net (loss) income…, Three Months Ended, , Nine Months Ended, , September 30,, , September 30,, , 2025, , 2024, , 2025, , 2024, Restructuring charges and asset write-offs (1) $ 0.02 $ 7.91 $ 0.03 $ 9.99 Goodwill impairment charges (2) 1.49 — 1.49 — Acquisition and integration related costs (3) 0.01 — 0.03 0.03 (Gain) loss in fair value of public equity securities (4) (0.05) 0.03 (0.02) 0.50 Other (5) 0.03 (0.04) 0.07 (0.23) Tax related items (6) 0.03 — 0.…, Loss before income taxes and equity in net income of unconsolidated investments, , Income tax (benefit) expense, , Effective income tax rate, , Three months ended September 30, 2025, As reported $ (239,146) $ (30,565) 12.8 % Non-recurring, other unusual and non-operating pension and OPEB items 181,424 1,210 As adjusted $ (57,722) $ (29,355) 50.9 % , Three months ended September 30, 2024, As reported $ (1,178,846) $ 110,853 (9.4) % Non-recurring, other unusual and non-operating pension and OPEB items 858,852 (69,575) As adjusted $ (319,994) $ 41,278 (12.9) % , Nine months ended September 30, 2025, As reported $ (267,083) $ (449) 0.2 % Non-recurring, other unusual and non-operating pension and OPEB items 202,805 11,789 As adjusted $ (64,278) $ 11,340 (17.6) % , Nine months ended September 30, 2024, As reported $ (1,840,552) $ 76,472 (4.2) % Non-recurring, other unusual and non-operating pension and OPEB items 1,227,924 25,642 As adjusted $ (612,628) $ 102,114 (16.7) % , Albemarle Investor Relations Contact: +1 (980) 308-6194,, [email protected], View original content to download multimedia: https://www.prnewswire.com/news-releases/albemarle-reports-third-quarter-2025-results-302606047.html SOURCE Albemarle Corporation Type: Article
GLP-1-Therapien revolutionieren die Behandlung von Diabetes und Adipositas und treiben beispiellose Nachfrage und Innovation voran. Während Pharmaunternehmen wetteifern, ihre Produktion zu skalieren und den Zugang zu erweitern, steht Albemarle als zuverlässiger Partner für Chemie bereit und liefert die Konsistenz und Kapazität, die zur Unterstützung dieser globalen Transformation erforderlich…
Type: Article
Type: Article
LP-1療法は、糖尿病および肥満治療のあり方を根本から変革し、かつてない需要とイノベーションを牽引しています。製薬企業が生産体制の拡大と治療へのアクセス向上を急ぐ中、アルベマールは信頼できる化学パートナーとして、精密性、一貫性、そしてこのグローバルな変革を支えるための供給能力を提供しています。
Type: Article
GLP-1 疗法正在彻底颠覆糖尿病和肥胖症的护理方式，并推动前所未有的需求和创新。随着制药公司相继扩大生产规模和应用范围，雅保作为值得信赖的化学合作伙伴已做好准备，亦将凭借精准性、稳定性和产能优势，为这场全球变革提供关键支持。
Type: Article
El retardante de llama de etilenobistetrabromoftalimida SAYTEX BT-93 es un aditivo único que combina bromo aromático estable con una estructura de imida. El retardante de llama SAYTEX BT-93 proporciona un rendimiento superior en una amplia variedad de aplicaciones. Se emplea en poliolefinas, poliestireno de alto impacto (HIPS), poliésteres termoplásticos (PBT, PET, etc.), policarbonato y…
Type: Product SKU
Az etilénbisztetrabróm-ftálimid SAYTEX BT-93 égésgátló egy egyedülálló adalék, amely stabil, aromás brómot kombinál egy imid szerkezettel. A SAYTEX BT-93 égésgátló prémium teljesítményt nyújt számos alkalmazásban. Használható poliolefinekben, nagy ütésállóságú polisztirolban (HIPS), termoplasztikus poliészterekben (PBT, PET stb.), polikarbonátban és elasztomerekben. A SAYTEX BT-93 égésgátló…
Type: Product SKU
エチレンビステトラブロモフタルイミドSAYTEX BT-93難燃剤は、安定した芳香族臭素とイミド構造を組み合わせた独自の添加剤。 SAYTEX BT-93難燃剤は、幅広い用途で最高の性能を発揮する。ポリオレフィン、高衝撃性ポリスチレン (HIPS)、熱可塑性ポリエステル (PBT、PET など)、ポリカーボネート、エラストマーなどに使用されている。 SAYTEX BT-93難燃剤は、優れた熱安定性とUV安定性を備えている。これは、最高度のUV安定性が要求される耐衝撃性ポリスチレン (HIPS) 配合物に最適な難燃剤である。熱安定性が高いため、ポリエステルやポリアミンなどのエンジニアリング樹脂に使用できる。SAYTEX BT-93難燃剤もブルーミングしない。この特徴により、優れたヒートシール性が要求されるポリオレフィンフィルムなどの重要な用途に使用することができる。優れた湿潤電気特性により…
Type: Product SKU